{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:45:19Z","timestamp":1768783519765,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102741","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:18:37Z","timestamp":1760545117000},"page":"102741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel eRF3a degrader enhances gentamicin-induced premature termination codon readthrough in epidermolysis bullosa"],"prefix":"10.1016","volume":"36","author":[{"given":"Kathleen L.","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Levian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingping","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-147X","authenticated-orcid":false,"given":"Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102741_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.abd.2020.05.001","article-title":"Inherited epidermolysis bullosa: update on the clinical and genetic aspects","volume":"95","author":"Mariath","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib2","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1038\/jid.1994.8","article-title":"Molecular basis of the dystrophic and junctional forms of epidermolysis bullosa: mutations in the type VII collagen and kalinin (laminin 5) genes","volume":"103","author":"Uitto","year":"1994","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/1523-1747.ep12365129","article-title":"Type VII collagen, anchoring fibrils, and epidermolysis bullosa","volume":"101","author":"Burgeson","year":"1993","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib4","series-title":"GeneReviews(\u00ae)","article-title":"Dystrophic Epidermolysis Bullosa","author":"Pfendner","year":"1993"},{"key":"10.1016\/j.omtn.2025.102741_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.det.2009.10.022","article-title":"Oral Manifestations in the Epidermolysis Bullosa Spectrum","volume":"28","author":"Wright","year":"2010","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.omtn.2025.102741_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/CCID.S54681","article-title":"Dystrophic epidermolysis bullosa: a review","volume":"8","author":"Shinkuma","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","article-title":"Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial","volume":"406","author":"Tang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102741_bib8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102741_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/bjd\/ljac001","article-title":"Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study","volume":"188","author":"Kern","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5582\/irdr.2017.01005","article-title":"Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Rashidghamat","year":"2017","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.omtn.2025.102741_bib11","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jid.2016.06.609","article-title":"Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa","volume":"136","author":"Hammersen","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4161\/cam.22418","article-title":"Laminin 332 in junctional epidermolysis bullosa","volume":"7","author":"Kiritsi","year":"2013","journal-title":"Cell Adh. Migr."},{"key":"10.1016\/j.omtn.2025.102741_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00439-004-1210-y","article-title":"Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease","volume":"116","author":"M\u00fchle","year":"2005","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102741_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2302\/kjm.2014-0013-RE","article-title":"Advances in gene\/cell therapy in epidermolysis bullosa","volume":"64","author":"Murauer","year":"2015","journal-title":"Keio J. Med."},{"key":"10.1016\/j.omtn.2025.102741_bib15","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.jid.5701197","article-title":"Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-\/- keratinocytes in vitro","volume":"128","author":"Igoucheva","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102741_bib17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102741_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","article-title":"Cause-specific risks of childhood death in inherited epidermolysis bullosa","volume":"152","author":"Fine","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtn.2025.102741_bib19","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102741_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jmg.2005.039685","article-title":"Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants","volume":"43","author":"Varki","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.omtn.2025.102741_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.molmed.2012.09.008","article-title":"Sense from nonsense: therapies for premature stop codon diseases","volume":"18","author":"Bidou","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2025.102741_bib22","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/mt.2014.140","article-title":"Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa","volume":"22","author":"Cogan","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102741_bib23","doi-asserted-by":"crossref","first-page":"E6536","DOI":"10.1073\/pnas.1803154115","article-title":"Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa","volume":"115","author":"Lincoln","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102741_bib24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/cells14151215","article-title":"Therapeutic opportunities in overcoming premature termination codons in epidermolysis bullosa via translational readthrough","volume":"14","author":"Miao","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102741_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000013861","article-title":"Aminoglycoside antibiotics","volume":"5","author":"Forge","year":"2000","journal-title":"Audiol. Neurootol."},{"key":"10.1016\/j.omtn.2025.102741_bib26","first-page":"27","article-title":"Aminoglycoside nephrotoxicity","volume":"17","author":"Swan","year":"1997","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.omtn.2025.102741_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102741_bib28","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2019-127892","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets GSPT1 for degradation to induce potent tumoricidal activity against acute myeloid leukemia (AML)","volume":"134","author":"Lopez-Girona","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102741_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2019-123966","article-title":"Clinical activity of CC-90009, a cereblon E3 ligase modulator and first-in-class GSPT1 degrader, as a single agent in patients with relapsed or refractory acute myeloid leukemia (R\/R AML): first results from a Phase I dose-finding study","volume":"134","author":"Uy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102741_bib30","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2019-128450","article-title":"A novel cereblon E3 ligase modulator eradicates acute myeloid leukemia stem cells through degradation of translation termination factor GSPT1","volume":"134","author":"Jin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102741_bib31","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood-2019-124291","article-title":"Pharmacodynamic responses to CC-90009, a novel cereblon E3 ligase modulator, in a phase I dose-escalation study in relapsed or refractory acute myeloid leukemia (R\/R AML)","volume":"134","author":"Fan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102741_bib32","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of small molecule eRF3 degraders on premature termination codon readthrough","volume":"49","author":"Baradaran-Heravi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102741_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292468","article-title":"Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene","volume":"18","author":"Palomar-Siles","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102741_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154571","article-title":"Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough","volume":"132","author":"Lee","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102741_bib35","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.jid.2024.02.027","article-title":"Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation","volume":"144","author":"Sayar","year":"2024","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/15476286.2023.2222250","article-title":"Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN","volume":"20","author":"Heldin","year":"2023","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2025.102741_bib37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng1041","article-title":"Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa","volume":"32","author":"Chen","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102741_bib38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/1523-1747.ep12491525","article-title":"Junctional epidermolysis bullosa keratinocytes in culture display adhesive, structural, and functional abnormalities","volume":"97","author":"Krueger","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.clpt.6100012","article-title":"Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy","volume":"81","author":"Zingman","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2025.102741_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system","volume":"80","author":"Keeling","year":"2002","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.omtn.2025.102741_bib41","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102741_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-4632.2006.02774.x","article-title":"Compound heterozygosity in sibling patients with recessive dystrophic epidermolysis bullosa associated with a mild phenotype","volume":"45","author":"Shibusawa","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jmg.2011.089615","article-title":"Efficiency of translation termination in humans is highly dependent upon nucleotides in the neighbourhood of a (premature) termination codon","volume":"48","author":"Pacho","year":"2011","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.omtn.2025.102741_bib44","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0002-9440(10)63762-5","article-title":"Keratinocytes from patients lacking collagen XVII display a migratory phenotype","volume":"164","author":"Tasanen","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102741_bib45","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ajpath.2017.03.003","article-title":"Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa","volume":"187","author":"Cianfarani","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102741_bib46","doi-asserted-by":"crossref","first-page":"17838","DOI":"10.1074\/jbc.M709452200","article-title":"Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis","volume":"283","author":"Woodley","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102741_bib47","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jid.2020.10.024","article-title":"Diversity of mechanisms underlying latent TGF-\u03b2 activation in recessive dystrophic epidermolysis bullosa","volume":"141","author":"Akasaka","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib48","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3390\/ijms22105104","article-title":"Impaired wound healing, fibrosis, and cancer: The paradigm of recessive dystrophic epidermolysis bullosa","volume":"22","author":"Tartaglia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102741_bib49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2021.5992","article-title":"Molecular and clinical outcomes after intravenous gentamicin treatment for patients with junctional epidermolysis bullosa caused by nonsense variants","volume":"158","author":"Mosallaei","year":"2022","journal-title":"JAMA Dermato"},{"key":"10.1016\/j.omtn.2025.102741_bib50","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"Woodley","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102741_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/bjd\/ljae063","article-title":"Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial","volume":"191","author":"Woodley","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib52","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/mt.2013.87","article-title":"Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure","volume":"21","author":"Wang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102741_bib53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","author":"Woodley","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102741_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102741_bib55","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1038\/jid.2015.291","article-title":"Intravenously administered recombinant human type VII collagen derived from chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice","volume":"135","author":"Hou","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102741_bib56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102741_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102741_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2025.102741_bib59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s43657-023-00142-w","article-title":"Expert consensus on big data collection of skin and appendage disease phenotypes in chinese","volume":"4","author":"Zhao","year":"2024","journal-title":"Phenomics"},{"key":"10.1016\/j.omtn.2025.102741_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02634257","article-title":"A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin","volume":"31","author":"Normand","year":"1995","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.omtn.2025.102741_bib61","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2020.03.006","article-title":"Gentamicin induces laminin 332 and improves wound healing in junctional epidermolysis bullosa patients with nonsense mutations","volume":"28","author":"Kwong","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102741_bib62","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jcp.1041360118","article-title":"Laminin inhibits human keratinocyte migration","volume":"136","author":"Woodley","year":"1988","journal-title":"J. Cell. Physiol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:01:47Z","timestamp":1766196107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125002951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125002951"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102741","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel eRF3a degrader enhances gentamicin-induced premature termination codon readthrough in epidermolysis bullosa","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102741"}}